High Therapeutic Efficacy of a New Survivin LSP-Cancer Vaccine Containing CD4⁺ and CD8⁺ T-Cell Epitopes.

ABSTRACT: The efficacy of an antitumoral vaccine relies both on the choice of the antigen targeted and on its design. The tumor antigen survivin is an attractive target to develop therapeutic cancer vaccines because of its restricted over-expression and vital functions in most human tumors. Accordingly, several clinical trials targeting survivin in various cancer indications have been conducted. Most of them relied on short peptide-based vaccines and showed promising, but limited clinical results. In this study, we investigated the immunogenicity and therapeutic efficacy of a new long synthetic peptide (LSP)-based cancer vaccine targeting the tumor antigen survivin (SVX). This SVX vaccine is composed of three long synthetic peptides containing several CD4⁺ and CD8⁺ T-cell epito

SUBMITTER: Onodi F 

PROVIDER: S-EPMC6243131 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature